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Abstract
Objective
Estimates indicate that 20–70% of renal transplant recipients are medication non-adherent,
significantly increasing the risk of organ rejection. Medication adherence is negatively
impacted by lower everyday problem solving ability, and associations between depressive
symptoms, self-efficacy, and adherence are reported in renal transplant recipients. Nonethe-
less, to date, these associations have not been examined concurrently. Given the relation-
ship between non-adherence and organ rejection, it is critical to gain a better understanding
of the predictors of adherence in renal transplant recipients. To this end, we modeled rela-
tionships among cognitive abilities, depressive symptoms, self-efficacy, and adherence in
this group.
Methods
Participants (N = 211) underwent renal transplant at least one year prior to participation.
Adherence was measured via self-report, medication possession ratio, and immunosup-
pressant blood-level. Traditionally-measured neurocognitive and everyday problem-solving
abilities were assessed. Depressive symptoms were measured via self-report, as were gen-
eral and medication adherence related self-efficacy. Structural equation modeling was used
to assess the fit of the model to available data.
Results
Everyday problem solving and self-efficacy had direct positive associations with adherence.
Depressive symptoms were negatively associated with self-efficacy, but not adherence.
Traditionally-measured neurocognitive abilities were positively associated with self-efficacy,
and negatively associated with depressive symptoms.
Conclusions
We present a comprehensive investigation of relationships between cognitive and psycho-
social factors and adherence in medically stable renal transplant recipients. Findings
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confirm the importance of everyday problem solving and self-efficacy in predicting adher-
ence and suggest that influences of depressive symptoms and neurocognitive abilities are
indirect. Findings have important implications for future development of interventions to
improve medication adherence in renal transplant recipients.
Introduction
Failing to adhere to immunosuppressant medications by renal transplant recipients (RTR) is
associated with elevated morbidity and mortality [1]. For instance, non-adherence is related to
a sevenfold increase in rates of graft rejection [2]. Graft rejection can lead to loss of the trans-
planted organ and a return to end stage renal disease, necessitating return to dialysis, re-
transplantation, or even causing death [1,3]. Despite potential dangers of failing to adhere to
immunosuppressant medications, rates of medication non-adherence by RTR range between
20–70% [4].
Existing research has identified several demographic and psychosocial factors related to
medication non-compliance in RTR [5,6]. For instance, social factors such as living alone and
being unmarried have previously been associated with decreased adherence, as have perceived
low level of social support, external locus of control, beliefs that medications are not required,
and higher levels of anxiety and hostility [6]. However, another risk factor that remains rela-
tively understudied to date involves the role of cognition. Indeed, relative to their healthy
peers, adults with chronic kidney disease (CKD) demonstrate weaknesses in memory and
executive functioning across the course of their illness [7,8] and following successful transplant
[9,10]. These cognitive difficulties in CKD and RTR have been theorized to stem from cerebro-
vascular insufficiencies commonly reported in CKD and in dialysis patients that may not be
reversed with transplantation [11].
Despite a paucity of research directly linking cognitive functioning and medication adher-
ence in RTR, several studies provide indirect evidence. Self-reported unintentional non-adher-
ence (forgetting) was identified as a probable source of non-adherence, with 62.4% of RTR
reporting such difficulties [12]. In another study, RTR surveyed cited barriers to adherence
that included difficulty reading medication instructions and remembering how many pills to
take and when [13]. These findings suggest that cognitive difficulties such as forgetfulness,
poor memory, and problems reading, understanding, or remembering instructions contribute
to non-adherence in RTR. Nonetheless, despite subjective associations between cognition and
adherence, none of the above studies with RTR objectively measured cognitive abilities (i.e.,
via structured neurocognitive assessments). Support for a relationship between cognitive func-
tioning and adherence is, however, found in other chronic illness populations. For example, in
persons receiving dialysis, non-adherent participants trend toward lower scores on a measure
of global cognitive ability [14]. Further, in HIV+ persons, better learning and memory, execu-
tive functioning [15], and working memory have been associated with increased adherence
[16].
Historically, cognitive functioning in chronic illness populations has focused on traditional
neurocognitive abilities (i.e., learning, memory, and executive functions [7,8,10]). Notably,
there is emerging interest in the role of "everyday" cognition, specifically, everyday problem
solving (EPS) in health behaviors. While performance on EPS tasks may in part rely on tradi-
tional abilities such as executive function and episodic memory [17,18], EPS appears to repre-
sent a distinct aspect of cognition with additive utility in predicting real world outcomes,
A model of medication adherence in renal transplant
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including self-rated functioning, life-skills functioning, and mortality [19–21]. Importantly,
past research indicates that better EPS performance predicts better self-reported medication
adherence in RTR [20]. Thus, not only must relationships between cognition and adherence
be further examined, but the differential impacts of traditional neurocognitive abilities and
EPS on medication adherence need to be established among RTR.
Another important factor to consider when examining adherence in RTR is depressive
symptomatology. Rates of depression in RTR are reported to be nearly 3 times higher than the
general US population (26% vs. 9.5%, respectively [22,23]). In fact, several studies have found
that self-reported depressive symptoms are associated with medication non-adherence in RTR
[12,20]. Previous research indicates that depression is not a unitary construct [24], yet research
examining the various aspects of depressive symptoms with RTR is sparse [25].
Association between poor performance on neurocognitive tests and depressive symptoms
are seen in other populations (e.g., traumatic brain injury [26], and older adults [27]). How-
ever, despite findings indicating that neurocognition and depressive symptoms vary together
among dialysis patients and RTR (i.e., neurocognitive abilities are higher, and depressive
symptoms lower, among RTR than dialysis patients [28]), few studies have examined associa-
tions between these two variables within RTR. In individuals with CKD however, negative
relationships are seen between performance on executive functioning tasks and depressive
symptoms [29]. Previously published research from our laboratory also suggests that decreased
EPS performance, along with increased depressive symptoms, predicts lower adherence in
RTR [20].
A related factor that is potentially critically important to medication non-adherence is self-
efficacy. Self-efficacy can be considered the antithesis of helplessness, a core facet of depressive
symptomatology [30]. Perceived self-efficacy involves one’s ability to change and adapt by
influencing how they envision their abilities and the limits of their capability [31]. Self-efficacy
can be examined generally by assessing willingness or ability to initiate behavior, put effort
into completing behaviors, and one’s persistence when faced with adversity [32]. Researchers
have also developed behavior-specific measures of self-efficacy, including those focusing on
adherence-related behaviors [33].
Existing research demonstrates links between self-efficacy and non-adherence in end stage
renal disease and RTR. For instance, both general [34], and adherence-related [35] self-efficacy
have been associated with treatment adherence in hemodialysis patients. Similarly, higher
adherence-related self-efficacy perceptions have been associated with better compliance with a
low fluid intake protocol for dialysis patients [36], and better medication adherence among
adult [37] and pediatric [38] RTR. Second only to side-effects complaints, Rudman and col-
leagues [3] report that adherence-related self-efficacy significantly predicts treatment compli-
ance in RTR. Despite indications in end stage renal disease that both general and specific self-
efficacy appraisals are associated with treatment adherence, the relative contributions of gen-
eral versus adherence-related self-efficacy in predicting medication adherence in RTR have
not been examined to date.
Importantly, the aforementioned link between non-adherence, cognition and depressive
symptoms may be at least partially explained by variations in self-efficacy. Previous findings
suggest that self-efficacy may mediate the association between neurocognitive abilities and
adherence in RTR [39]. Higher self-efficacy has also been linked to lower depressive and
somatic symptoms, pessimism, and interpersonal vulnerability in RTR [40,41]. Research with
other populations including hemodialysis patients [35] indicates that self-efficacy may mediate
the relationship between depressive symptoms and adherence [42]. Thus, self-efficacy may
account (in whole or in part) for associations between these cognitive and affective variables
and non-adherence in RTR.
A model of medication adherence in renal transplant
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To address these issues and advance our understanding of the interplay between these psy-
chosocial and neurocognitive variables in RTR, the current study examined the interrelations
of medication adherence (in the present study, specifically implementation adherence—
defined here as the extent to which an individual’s actual dosing reflects their prescribed medi-
cation regimen [43]), depressive symptoms, self-efficacy, EPS, and neurocognitive abilities to
clarify relationships between these variables previously only examined via univariate methods.
This multivariate approach allowed us to simultaneously model our four latent independent
variables, interrelatedness among these latent variables, and the relative importance of each as
a predictor of medication adherence in RTR. Our multivariate model includes neurocognitive
abilities (i.e., intelligence, executive functions, and memory), EPS, depressive symptoms
(depressed affect, absence of well-being, somatic symptoms, and interpersonal rejection), and
self-efficacy (both general and adherence-related appraisals), to examine direct and indirect
associations between these variables and medication adherence. To our knowledge, this repre-
sents the first comprehensive multivariate investigation of cognitive abilities, depressive symp-
toms, and self-efficacy in relation to adherence in a sample of RTR.
We hypothesized that better performance on neurocognitive and EPS measures would pre-
dict better adherence. Also consistent with past work in RTR and other clinical populations
[20,42], we hypothesized that depressive symptoms would directly, negatively, predict this type
of adherence in RTR. In line with documented associations between self-efficacy and adher-
ence [37], we hypothesized that self-efficacy would directly predict adherence. Finally, given
evidence of the mediating role of self-efficacy in the association of adherence with depression
[42] and aspects of cognition [39], we hypothesized that self-efficacy would mediate associa-
tions between neurocognitive abilities, EPS, depressive symptoms, and adherence (Fig 1).
Given that both general and adherence-specific self-efficacy were measured, we also hypothe-
sized that general self-efficacy would be of greater relative importance as general self-appraisals
are thought to better reflect trait features than adherence specific appraisals [44].
Materials and methods
Participants
Between 2011–2014, 228 participants were recruited from the Solid Organ Transplant Clinic
at Vancouver General Hospital, Vancouver (BC), Canada. Eligible, participants met the follow-
ing criteria: 1) successful kidney graft at least one year prior to recruitment; 2) adequate vision
(i.e., equal to or better than 20/70, corrected or not [45]) and hearing (corrected or not), and
free of other sensory impairments that would significantly interfere with testing; 3) sufficient
English fluency; 4) education of at least a 6th grade level to ensure adequate comprehension of
written materials; 5) stable renal functioning determined by estimated glomerular filtration
rate (eGFR, an estimation of filtration capacity of the functioning nephrons and measure of
kidney reserve) above 14ml/minute per 1.73 m2. Exclusion criteria included the diagnosis of a
psychotic disorder, acute physical illness, a diagnosed neurological disorder (e.g., Parkinson’s
disease), or any other major organ failure (e.g., end stage liver disease). A flow chart describing
participant recruitment and participation is presented in Fig 2.
Prospective participants were mailed study invitation letters and follow-up phone calls to
interested participants were made by trained research assistants. All participants signed letters
of informed consent and received $30. Testing conducted individually, by trained examiners,
required approximately 1.5–2 hours. This study was approved by the Simon Fraser University
Research Ethics Board (dore@sfu.ca; application number 2010s0574), and by the University of
British Columbia (https://ethics.research.ubc.ca; application number H04-80470) and the
Vancouver Coastal Health Authority (www.vchri.ca; application number V04-0252).
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Measured variables
Demographics and clinical data. All measures were administered by trained research
assistants. Information on various illness variables was collected via self-report and existing
medical records. Participants reported their age, gender, level of education, ethnicity, and liv-
ing situation. Health variables included time since transplant, number of transplants received,
donor type (living or cadaveric), CKD stage, time on dialysis prior to transplant, CKD diagno-
sis, history/current diagnosis of diabetes, and eGFR and hemoglobin levels (g/L; low levels are
indicative of anemia).
Depressive symptoms. The Center for Epidemiological Studies Depression Scale (CES-D
[46]) is a commonly used 20-item scale measuring the frequency of various depressive symp-
toms. Factor analyses with various populations (including pre and post renal transplant) have
identified four separate factors labeled Depressed Affect, Absence of Well-Being, Somatic
Symptoms, and Interpersonal Rejection that contribute significantly to measurement of a
higher-order depression construct [24,25,47,48]. These individual factors were retained in the
current study to allow examination of the role of each in predicting adherence.
Self-efficacy. We utilized well-established measures of both General self-efficacy and
Medication Adherence specific self-efficacy. General self-efficacy was assessed with three dif-
ferent self-report measures, so as to provide multiple discrete observed variables for inclusion
Fig 1. Initial estimated model of adherence by renal transplant recipients. Edu. = years of education, Eth. = ethnicity, Socio Dem = Socio-demographic latent
variable, Dep. = CES-D Depressed affect, Well = CES-D Absence of Wellbeing, Som. = CES-D Somatic Symptoms, Interpers. = CES-D Interpersonal Rejection,
SE = Self-Efficacy scale, GSE = General Self-Efficacy scale, NGSE = New General Self-Efficacy Scale, MASES = Medication Adherence Self-Efficacy Scale—Revised,
TxASES = Transplant—Adherence Self-Efficacy Scale, ADH2 = TxEQ Adherence question 2, ADH7 = TxEQ Adherence question 7, ADH11 = TxEQ Adherence
question 11, ADH20 = TxEQ Adherence question 20, ADH22 = TxEQ Adherence question 22, LNS = WAIS Letter-number sequencing, DSC = WAIS-Digit
Symbol Coding, Trails = Trails Number-Letter Switching, CW = Color-Word Inhibition, CVLT-II = CVLT—Long Delay Free Recall, KBIT-2 = KBIT-2 IQ
composite, Q. A through Q. F = EPS Test questions A through F.
https://doi.org/10.1371/journal.pone.0204219.g001
A model of medication adherence in renal transplant
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Fig 2. Participant recruitment flow chart. Note: Regarding inclusion/exclusion criteria at intake, participants who indicated less than 3 of 4 preferences as “English”
for speaking, reading, writing, and thinking, on an acculturation questionnaire were considered ineligible due to language requirements for neurocognitive testing; in
addition, those reporting any of the abovementioned physical or mental health exclusions were ineligible; Not interested = participants who declined study
participation due to lack of interest; Not scheduled = participants who expressed interest in the study, but who had scheduling conflicts, and did not participate.
https://doi.org/10.1371/journal.pone.0204219.g002
A model of medication adherence in renal transplant
PLOS ONE | https://doi.org/10.1371/journal.pone.0204219 September 28, 2018 6 / 20
within the hypothesized self-efficacy latent construct, given that latent variables in SEM should
ideally include at least 3 observed variables [49]. The 30-item Self-Efficacy Scale was developed
by Sherer and colleagues [32] to evaluate general and social self-efficacy. The General Self-Effi-
cacy Scale (GSE [50]) was created to assess a general sense of perceived self-efficacy to predict
coping with daily hassles and adaptation to various types of stressful life events. The New Gen-
eral Self-Efficacy Scale (NGSE [51]) was created to provide a more concise and valid update to
the general self-efficacy subscale of the abovementioned Self-Efficacy Scale published by Sherer
and colleagues [32].
Medication adherence-specific self-efficacy was measured with two self-report question-
naires. The Adherence Self-Efficacy Scale (ASES [52]) was slightly modified for RTR research,
with one HIV-specific item removed. Respondents rate their efficacy to carry out important
treatment-related behaviors including medication adherence in the face of possible barriers.
The Medication Adherence Self-Efficacy Scale—Revised (MASES-R [33]) asks individuals to
assess their ability to carry out important medication adherence-related actions when faced
with various possible stresses.
Neurocognitive measures. Well-established tasks assessing multiple cognitive domains
were utilized to provide measurement of aspects of cognition commonly examined in RTR
[7,8,10]. The Kaufman Brief Intelligence Test (KBIT-2 [53]) assesses verbal and non-verbal
intellectual functioning. The Verbal scale contains both a Verbal Knowledge task (assessing
general information and word knowledge), and the Riddles task (assessing verbal concept for-
mation). The Nonverbal scale consists of the Matrices task (assessing nonverbal reasoning).
The California Verbal Learning Test (CVLT-II [54]) was used to assess verbal memory. The
Long-Delay Free Recall [LDFR] score was examined, providing an estimate of participants’
ability to retain verbal information. The Delis–Kaplan Executive Function System (D-KEFS
[55]) assesses aspects of executive functioning. Trial 4 (Letter-Number Sequencing) of the
Trail Making Test of this battery is used as a measure of set-shifting [56], and Trial 3 (Inhibi-
tion) of the Color-Word Interference task is used as a measure of cognitive inhibition [57]. The
Digit Symbol-coding subtest of the Wechsler Adult Intelligence Scale III (WAIS-III [58]) is a mea-
sure of processing speed, with the total number of correctly matched items within 120 seconds
as the outcome measure. Working memory was assessed with the Letter-Number Sequencing
subtest (WAIS-III [58]), with the number of successively longer reordered number-letter spans
produced as the outcome variable.
Everyday problem-solving. The Everyday Problem Solving (EPS) task consists of six paper
and pencil vignettes used in previous research [18–20,59,60]. Participants are instructed to
read each problem carefully, record as many solutions as possible, and include all solutions,
even those that they themselves would not consider using. Problems are structured to allow for
generation of multiple responses (e.g., “An elderly man has just retired. He doesn’t have any
hobbies because he has never had time for them before. Now he is really bored. What should
he do?”), and the number of safe and effective solutions generated was used as the outcome
measure. Inter-rater agreement seen in previous research among CKD patients, using these
scoring criteria, has been very high (e.g., ric = .96 [18]). Inter-rater reliability was similarly high
in the current study (ric = .94).
Medication adherence. Prior to cognitive assessment, participants’ three most recent
cyclosporine/tacrolimus serum levels were noted from medical records. Serum immunosup-
pressant levels were classified as “at target level” if two or three of three levels were within the
target range for that medication. They were classified as ‘not at target level’ if less than two lev-
els were within target range (450 ng/mL or higher at 2 hours (C2) post dose for cyclosporine;
4–8 ng/mL measured on the trough (or c0) level for tacrolimus). Transplant recipients fol-
lowed at the Solid Organ Transplant clinic undergo routine medication serum level
A model of medication adherence in renal transplant
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monitoring on approximately a monthly basis, so information collected generally reflects the
three-month period prior to neurocognitive assessment.
Pharmacy refill data for participants’ primary immunosuppressant medication was used to
calculate a medication possession ratio (MPR), indicating the percentage of prescribed medi-
cation an individual obtained within a specified period, compared to that which they should
have obtained during that period.
Participants completed the Adherence subscale of the Transplant Effects Questionnaire
(TxEQ [61]) to assess how well they were adhering to their medication regimen (e.g. “Some-
times I forget to take my antirejection medicines”). Items are endorsed on a 5-point Likert
type scale (“Strongly Agree” to “Strongly Disagree”) with total score range of 5–25 for this sub-
scale, and higher scores indicating better adherence [61]. Work by Frazier and colleagues indi-
cates that measurement of non-adherence is improved by use of a continuous measure, which
unlike many self-report scales utilizing ‘yes’ or ‘no’ responses, the TxEQ allows [62]. Similarly,
previous research indicates that self-report measures that ask for qualitative reports of adher-
ence better approximate adherence level as measured by electronic monitoring than those que-
rying specification of missed doses [63].
In a systematic review, the TxEQ Adherence scale has been shown to have good reliability
and established content validity [64]. Test-retest reliability of responses to this scale after a
1-month interval is high (r = .77 [61]). Internal consistency of this scale is also satisfactory (α =
.78), while convergent and divergent validity analyses demonstrate correlations between con-
scientiousness, neuroticism, emotional coping, and the Adherence scale [65]. Responses to the
five TxEQ Adherence items have also been shown to significantly correlate with quality of life
related to health in RTR [66].
Data analyses
Statistical methodology. Structural equation modeling (SEM) was used to test the mathe-
matical viability of an omnibus multivariate model of predictors of treatment adherence
among individuals greater than one year post renal transplant. Neurocognitive Abilities,
Everyday Problem-Solving, Depression, Self-Efficacy, and Medication Adherence served as
latent variables represented by scores on the specific (observed) measures described above. As
SEM is a confirmatory form of analysis, use of this technique allowed us to test the theorized
causal model seen in Fig 1. Various goodness of fit indices are used to assess model fit to data
in structural equation modeling. As recommended by O’Rourke and Hatcher [49], we report
incremental, absolute, and parsimonious goodness of fit indices.
The Comparative Fit Index (CFI) provides a measure of incremental or relative fit. The CFI
is thought to be the best index in covariance structure analyses, with little sampling variability
for a relative fit index [67]. Values greater than .94 indicate good fit between the proposed
model and actual data [68].
The Root Mean Square Error of Approximation (RMSEA) is a parsimony index and Stan-
dardized Root Mean Square Residual (SRMR) is an absolute fit index. For both, values less
than .09 indicate adequate fit [69] and values less than .055 indicate good fit [49]. The 90%
confidence interval is also often reported for the RMSEA, with a related test referred to as p of
Close Fit (pCLOSE). This latter measure is a test of the null hypothesis that the RMSEA is .05.
As such, a non-significant result on this test indicates a “close” fit of the proposed model [69].
The SRMR measures the difference between observed and predicted correlation.
Model development. The goal of this study was to provide an examination of the relation-
ships between latent constructs as opposed to an in-depth examination of the separate aspects
of neurocognitive abilities, depression and self-efficacy. Therefore, all of our neurocognitive
A model of medication adherence in renal transplant
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measures were included on a single latent variable, a decision supported by previous research
examining neurocognitive functioning in RTR that has shown significant covariance among
neurocognitive tasks in this population [20], Similarly, all aspects of depression, and types of
self-efficacy measured, were each included on a single latent variable, respectively.
Variables previously associated with adherence in solid organ transplant research were con-
sidered for inclusion on a prospective socio-demographic latent variable to account for addi-
tional impact these variables may have on adherence. Correlations were examined between
our adherence measures (TxEQ Adherence, immunosuppressant target, and MPR) and possi-
ble covariates including age, living situation (alone vs. with others), level of education, gender
[6], ethnicity (Caucasian vs. non-Caucasian [70]), donor type (relative vs. unrelated [71]), time
since most recent transplant, and level of employment (more or less than 20 hours per week
[72]). Significant correlations were seen only for gender and ethnicity. Although neither age
nor level of education correlated with any of our three adherence measures in these prelimi-
nary analyses, these two covariates were also initially retained in the originally proposed model
due to their impact on neurocognitive and EPS measures in previous research [9,18].
Confirmatory factor analyses. As an initial step in testing our model, we used confirma-
tory factor analyses to test the viability of measurement models for each of our latent variables
without causal paths between them. For all latent constructs described above, measured vari-
ables loaded onto their respective latent variables, with the exception of the adherence latent
construct. For the conceptualized adherence construct (i.e., five items that make up the TxEQ
Adherence scale, immunosuppressant target, and MPR) the latter two variables did not load
onto the same factor as the five TxEQ items. As a result, target level and MPR were removed
and placed on a second adherence variable; however, these two variables again did not load
onto the same factor and were thus removed from the subsequent SEM analyses. The CFI and
RMSEA of the final adherence latent variable were optimal (CFI = 1.00; RMSEA = .005;
Table 1 shows lack of significant correlations between the adherence variables). Fit indices for
the remaining latent variables were all acceptable (EPS: CFI = .99; RMSEA = .052; depression:
CFI = 1.00; RMSEA < .001; self-efficacy: CFI = 1.00; RMSEA < .001; traditional neurocogni-
tion: CFI = .98; RMSEA = .071).
Given the results of the CFA, immunosuppressant target level and MPR data were not
included in the tested model, which relied instead on a previously validated self-report adher-
ence measure shown to have good reliability in transplant samples [73]. The inability of the
three adherence measures to load on the same construct highlights discrepancies in what these
methods measure. Previous research suggests mixed results with respect to agreement between
measurement methods [20,74,75]. The fact that each of these measures captures a different
facet of adherence (i.e., blood level of medication, medication used over a period, self-reported
estimates of adherence behaviors) may explain non-significant correlations between measures
in this and other samples.
With this in mind, previous research indicates that self-report measures better approximate
adherence as measured via electronic pill-top monitoring devices than do other forms of
adherence assessment [2], and provide the most conservative estimate of adherence in RTR
according to meta-analytic review (i.e., highest rates of non-adherence) [70]. Unlike the other
Table 1. Correlation Matrix for adherence variables.
Target MPR TxEQ
Target - -
MPR -.019 - -
TxEQ .042 .125 - -
p  < 0.050, (There are no significant correlations).
https://doi.org/10.1371/journal.pone.0204219.t001
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measures of adherence considered in the present study, measures that rely on self-report are
not affected by medication half-life and may, unlike refill data, provide an indication of
whether medications that were picked up, were ingested.
Pitfalls of immunosuppressant blood level and MPR measures have been shown to include
individuals’ increasing adherence behaviors just prior to clinic visits where blood is taken, or
stockpiling medications retrieved from the pharmacy [76]. MPR data in the present study are
at ceiling (M = .99), supporting assertions that this method can overestimate adherence [76].
Serum level measurements may also underestimate adherence due to half-life of the medica-
tion [77], and are further impacted by differences in pharmacodynamics and pharmacokinet-
ics of medications both within and between individuals, type of analytical methods used to
determine serum concentration, and potential for interactions between multiple medications,
with dietary factors, and with comorbid diseases [77,78].
Results
Descriptive statistics
The study sample was 59.7% male, with significantly more men than women (t[210] = 41.45, p
< .001). Of note, 20% of the sample scored above the CES-D threshold value suggestive of clin-
ically significant depressive symptoms. Approximately 90% of participants were in stages 1–3
of CKD based on eGFR levels, indicating they may have at most some mild symptoms includ-
ing tiredness, poor appetite, and/or itching associated with kidney dysfunction [79]. Fewer
than 10% were in stage 4, in which patients commonly experience more pronounced physical
symptomatology (see Table 2). No differences in adherence were seen between those with first
vs. second transplants, or those who received living vs. deceased donor transplants. Time since
transplant ranged from 1.17 to 30.5 years, with 15.6% of the sample having received their
transplant within the previous 3 years.
Fifteen participants were removed from the SEM analyses due to missing data (14 with sub-
stantial non-random missing data; 1 missing demographic data that could not be imputed).
For included participants, missing data were minimal for most variables examined (generally
1–2 missing values per variable). Multiple imputation was used to provide complete data for
Maximum Likelihood methods in AMOS [80]. Results were confirmed using Full Information
Maximum Likelihood methods to allow for missing data.
Estimation of initial model
The baseline model included some non-significant paths. After correcting for correlations
between 30 pairs of error terms, model fit was improved, χ2[df = 365] = 601.326, p< .001.
However, some of the fit indices suggested the model was not a good fit to the data. The
RMSEA indicated adequate fit (RMSEA = .056, CI: .047-.063; pCLOSE = .13), but values for
the CFI (.88) and the SRMR (.097) fell below ideal limits. Also of note, originally hypothesized
pathways between neurocognitive abilities and self-efficacy, neurocognitive abilities and
adherence, EPS and self-efficacy, and depressive symptoms and adherence were not statisti-
cally significant. Additionally, none of the four socio-demographic variables loaded onto that
latent variable, and the pathways from the socio-demographic variable to traditional neurocog-
nition and to EPS were not significant.
Revision and estimation of final model
Revisions were made to improve model fit to the data. Age and gender were removed from the
socio-demographic latent variable, leaving education and ethnicity, and with these changes,
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Table 2. Sample demographic and measurement characteristics.
Participant Characteristics Study Sample (N = 211)
Age 53.93 ± 11.91
Male 126 (59.7%)
Ethnicity
Caucasian 137 (64.9%)
Asian 41 (19.4%)
Other 33 (15.7%)
Education 13.96 ± 2.35
Living Situation
Alone 30 (14.2%)
With Spouse 147 (69.7%)
With Other 34 (16.1%)
Distance from Clinic
<1 mile 8 (3.8%)
1–10 miles 71 (33.6%)
10–30 miles 94 (44.5%)
30–100miles 37 (17.5%)
Number of Renal Transplants (> 1) 21 (10.0%)
Transplant type (deceased donor) 102 (48.6%)
Time Since Transplant (years) 8.98 ± 6.74
Time on Dialysis Pre-transplant (years) 2.34 ± 2.42
Hemoglobin Level (gm/L) 131.38 ± 17.39
eGFR Level (ml/min) 56.42 ± 19.74
CKD Stage
1 (eGFR 90) 13 (6.2%)
2 (eGFR = 60–89) 76 (36.4%)
3 (eGFR = 30–59) 100 (47.8%)
4 (eGFR = 15–29) 20 (9.6%)
Study Measures M (SD) N (%)
CES-D 9.76 (8.39)
CES-D Score >15 44 (20.9%)
GSE 32.79 (4.82)
SE 85.35 (12.44)
NGSE 31.89 (5.55)
Tx-ASES 101.15 (11.70)
MASES-R 49.26 (4.66)
KBIT-2 101.49 (13.13)
DKEFS CW 10.67 (2.80)
DKEFS Trails 10.24 (3.15)
CVLT-II .41 (1.06)
WAIS LNS 10.86 (3.01)
WAIS DSC 8.35 (3.05)
EPS 24.03 (7.72)
TxEQ 21.26 (3.79)
MPR .99 (.12)
(Continued)
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pathways from the modified socio-demographic variable (accounting for ethnicity and educa-
tion) to neurocognition and EPS were significant. To ensure the best model fit, a specification
search was conducted in AMOS with nonsignificant paths between latent constructs included
in the original model considered as optional paths. Parameters for alternative models were
examined to determine which paths should and should not be removed. The path from neuro-
cognitive abilities to self-efficacy was retained, however when this model was examined, this
path remained nonsignificant, and the path between EPS and depression was also nonsignifi-
cant. A subsequent specification search was conducted with these two paths considered
optional, and the most parsimonious model was that in which the path between EPS and
depression was removed. This model was again examined and the path between neurocogni-
tive ability and self-efficacy was significant, and thus retained within our final model. It is pos-
sible that given the relationship between depression and self-efficacy, the path from EPS to
depression had a suppressing effect on the relationship between neurocognitive abilities and
self-efficacy in our original model.
In our final model, both EPS and self-efficacy directly positively predicted medication
adherence, while neurocognitive abilities and depressive symptoms did not. Neurocognitive
abilities did both positively predict self-efficacy and inversely predict depressive symptoms,
while depressive symptoms inversely predicted self-efficacy, indicating both direct and indirect
relationships between neurocognitive abilities and self-efficacy (Fig 3). All paths that remained
between latent constructs were statistically significant, and all parameter estimates were statis-
tically significant. Based on the formula first reported by Maccallum and colleagues [69], statis-
tical power for the resulting model was estimated at .99. Given the multiple hypotheses tested
in the present model, we used the Benjamini-Hochberg [81] method of controlling false dis-
covery rate (FDR) with adjusted p-values calculated via a spreadsheet program developed by
McDonald [82]. All evaluated hypotheses remained significant.
Goodness of fit indices indicated acceptable fit between data and the revised model, χ2
(df = 313) = 376.24, p = .009. The SRMR (.072) is satisfactory, whereas values for the CFI (.97),
and the RMSEA (.031) are both ideal. Moreover, the full range of the 90% confidence interval
for the RMSEA was within ideal parameters (.017-.042), indicating that the hypothesis of a
non-close fit can be rejected (PCLOSE = 0.99 [69]).
Table 2. (Continued)
Target (on target) 161 (85.2%)
Note: Mean (M) and standard deviation (SD) for continuous variables; frequency (N) and percentage (%) for
dichotomous variables. Higher scores = better performance (except CES-D—higher scores indicate increased
symptoms).
CES-D = Center for Epidemiological Studies Depression Scale (range: 0–60; 16 = clinically significant
symptomatology). GSE = General Self-Efficacy Scale (range: 10–40); SE = Self-Efficacy Scale (range: 30–150);
NGSE = New General Self-Efficacy Scale (range 8–40); Tx-ASES = Transplant—Adherence Self-Efficacy Scale (range:
11–110); MASES-R = Medication Adherence Self-Efficacy Scale—Revised (range: 13–52).
For traditional neurocognitive measures, standard (M = 100, SD = 15), scaled (M = 10, SD = 3), or Z-scores (M = 0,
SD = 1) are reported; study M (SD) indicated. KBIT-2 = KBIT-2 IQ Composite score; D-KEFS CW = D-KEFS Color-
Word Interference Trial 3; D-KEFS Trails = D-KEFS Trail Making Test Trial 4; CVLT-II = CVLT-II Long Delay Free
Recall; LNS = WAIS-III Letter Number Sequencing; DSC = WAIS-III Digit Symbol-Coding.
EPS = Everyday Problem Solving test (theoretical range: 0-infinite); TxEQ = Transplant Effects Questionnaire—
Adherence (range: 5–25); MPR = medication possession ratio: Target = cyclosporine/tacrolimus serum on/off target
(dichotomous).
https://doi.org/10.1371/journal.pone.0204219.t002
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Discussion
To these authors’ knowledge, these findings represent the first approach to modeling concomi-
tant relationships between medication adherence (i.e., implementation adherence) and rele-
vant cognitive, affective, and psychosocial factors with RTR in medically stable transplant
recipients. This model highlights the importance of EPS ability and self-efficacy appraisals in
predicting self-reported medication adherence. The model also provides important insights in
relation to indirect relationships between neurocognitive abilities and depressive symptoms,
respectively, and self-reported adherence, suggesting that the respective influences of these
variables on adherence are not as direct as has generally been reported by the extant literature
to date.
Our results provide important insights into the interrelations between variables related to
longer term adherence that have previously only been examined independently of one another.
In the context of the current model, both self-efficacy and EPS directly positively predict self-
reported adherence. Neither depressive symptoms nor neurocognitive abilities are directly
associated with adherence. While EPS is directly related to adherence (as in previous research
[20]), self-efficacy mediates the relationship between neurocognitive abilities and adherence.
This mediating effect of self-efficacy indicates the important role of self-efficacy in predicting
adherence, whereas neurocognitive abilities appear to have a more indirect role in medication
adherence (via self-efficacy and depressive symptoms). As research examining these variables
is limited to date, these findings represent an important step forward in our understanding of
the relationships between cognition, self-efficacy, and adherence in RTR.
Fig 3. Final revised model of medication adherence among renal transplant recipients. Parameters are noted as standardized regression weights. Statistically
significant CR values (in parentheses) are greater than |1.96|.
https://doi.org/10.1371/journal.pone.0204219.g003
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Interestingly, measures of adherence-related self-efficacy were seen to have higher loadings
on the self-efficacy latent construct than general self-efficacy measures, suggesting that adher-
ence-related measures make a greater contribution to the self-efficacy construct among RTR.
Given the importance of self-efficacy in the prediction of adherence, future research should
focus on examining the relative impact of both general and adherence-related self-efficacy on
medication adherence in RTR.
The relationships observed between neurocognitive abilities and EPS with adherence high-
light important differences in the predictive utility of these measures for adherence in individ-
uals who have been transplanted for over a year. EPS predicts self-reported adherence directly
and independently from the effects of all other considered variables in the current sample. The
EPS measure used in this study requires participants to generate multiple safe and effective
solutions to problems (see [83] for a review). As such, better performance on this task is
thought to reflect the ability to generate multiple efficacious solutions to problems that may
arise (e.g., how to avoid missing a dose of medication when out of the house, when at work,
when feeling ill, and under other circumstances). Future research examining EPS in relation to
adherence in RTR and other groups is warranted. The roles of self-efficacy and EPS also pin-
point potential targets for future interventions to increase medication adherence across the
lifespan.
The absence of a direct effect of depressive symptoms on adherence ran counter to the
hypotheses. In the revised model, depressive symptoms were negatively related to self-efficacy,
which in turn, was directly, positively, related to self-reported adherence. The path through
self-efficacy between depressive symptoms and adherence highlights the importance of self-
efficacy ratings in the prediction of adherence. Past findings of associations between depressive
symptoms and adherence have failed to account for this influence of self-efficacy [20]. In our
revised model, direct relationships were also observed between neurocognitive abilities and
both depressive symptoms and self-efficacy, indicating that better cognitive abilities are associ-
ated with both higher self-efficacy and lower depressive symptoms. Consistent with past
research [23], 21% of the study sample scored above a clinical cut-off for depression, thus, rela-
tionships between these variables deserve increased attention going forward.
Understanding the interplay between cognition, depressive symptoms, and self-efficacy
appraisals in impacting self-reported medication adherence one year or more post-transplant
will better enable practitioners to flag individuals at risk for non-adherence over the longer
term. This can also enable follow-up care by psychologists or social workers who may be able
to provide targeted assessment of cognition, mood and/or adherence-related self-efficacy, as
well as applicable interventions tailored to each RTR’s specific challenges. Further, these find-
ings highlight the need for development and implementation of interventions that focus on
increasing general and adherence-related self-efficacy, improving/compensating for EPS diffi-
culties, and decreasing depressive symptoms. Research is needed to develop novel interven-
tions to improve adherence, and effectually, real-world function and quality of life post-
transplant. Future research should also focus on development and piloting of predictive adher-
ence measures utilizing EPS and self-efficacy appraisals, with focus on easily administered
measures that can be utilized by health care practitioners.
Limitations and conclusions
Limitations of the present study warrant mention. First, the study sample was derived from
one transplant center in western Canada. It will be important to replicate findings in other
groups of RTR from different regions in Canada, the United States, and abroad, to examine
whether findings generalize to other samples.
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The cross-sectional nature of this study also precludes definitive conclusions regarding the
causality of observed relationships. Many of the variables examined in the present study may
fluctuate for an individual across time (e.g., level of depressive symptomatology, level of self-
efficacy both in general and in relation to adherence), as such, longitudinal studies are needed
to examine how these constructs vary in relation to one another over time. Time since trans-
plant in our sample was also greater than one year, with a focus on variables of possible impact
on adherence across the lifespan as opposed to factors which may preferentially impact acute
adjustment to adherence regimen post-transplant. The current model is thus likely not accu-
rate to the initial adjustment phases of adherence post-transplant, and future research testing
this model with samples at various time-points post-transplant would be beneficial. Addition-
ally, availability of participants precluded the inclusion of an additional hold-out sample with
which to externally assess our final multivariate model. As such, these analyses should be con-
sidered exploratory, and for this reason as well, should be confirmed with another sample of
RTR.
Finally, as noted above, the model did not include immunosuppressant target level or MPR
data, relying on self-reported adherence. As discussed, the failure of these distinct measures to
load on one construct highlights dissociations and mixed agreement between these forms of
measurement previously reported in the literature [20,71,72], likely related to the fact that each
captures a different facet of adherence (i.e., blood level, medication collected, self-reported
behavior). Although previous research has indicated that self-report measures better approxi-
mate adherence as measured via electronic pill-top monitoring devices than do other forms of
adherence assessment [2], and provide the most conservative estimate of adherence in RTR
[70], thus justifying use of self-report measures in adherence research, future research should
certainly aim to reconcile these different measurement methods. Future research that exam-
ines models of relationships between immunosuppressant level data and MPR measures of
adherence, respectively, and cognitive and psychosocial constructs, are an important next step
given the present results. It will be important to determine whether similar relationships are
seen between cognitive and psychosocial variables and these different types of adherence mea-
sures in RTR. Additionally, it will be important to replicate these findings using other self-
report measures of adherence to confirm the relationships seen in the present study.
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